Scribe Therapeutics, Inc. (SCTX) stock
SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)
Close on Nov 17, 2026Market cap $39.19MP/E –Yield –
Scribe Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
No ebitda figures for Scribe Therapeutics
Scribe Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?